Medicare Covers Obesity Now. Almost Nobody Knows.

The law that said no, and the workaround that said yes

Social Security Act §1860D-2(e)(2)(A) · CMS, Contract Year 2026 Policy and Technical Changes, final rule, April 2025

Since Part D began in 2006, the statute has excluded agents when used for weight loss from Medicare coverage, borrowing the same exclusion list Medicaid has used since 1990. For twenty years Medicare paid for the bypass, the dialysis, the insulin, and the joint replacement, but not the treatment upstream of all of it.

The exclusion is about the indication, not the molecule. Part D has always covered semaglutide and tirzepatide for type 2 diabetes. Then each new FDA label opened another door: Wegovy for cardiovascular risk reduction in March 2024, Zepbound for obstructive sleep apnea in December 2024, Wegovy for MASH in August 2025. If a patient had one of those diagnoses, the drug was covered. If the problem was obesity itself, it was not.

In November 2024 CMS proposed reinterpreting the exclusion so that treating obesity would count as treating a chronic disease. The final rule in April 2025 dropped it. So what happened on July 1 is not a change in the law. It is demonstration authority: the GLP-1 Bridge runs outside Part D, funded and administered by CMS directly, so no plan carries the risk and the statute is left alone.

When Fox 10 asked me in June whether these medications should be covered, I gave the answer I will give here. I am not treating people for weight loss. I am treating obesity, which is a disease with complications we already pay for at the back end. The statute is written as though those two things are the same. They are not, and until that sentence changes, everything we are about to walk through has an expiration date on it.

The $50 grid, and who actually fits in it

CMS, Medicare GLP-1 Bridge: Information for Providers, updated August 6, 2026 · KFF, July 2026

The Bridge runs July 1, 2026 through December 31, 2027, extended in the spring from its original end date of December 31, 2026. It sets a flat $50 per prescription for Foundayo (orforglipron), Wegovy in both the injection and the tablet, and Zepbound in the KwikPen only. Zepbound vials and single-dose pens are not included, which has already tripped up more than one refill in my clinic.

Eligibility is a grid, not a label. BMI 35 or higher qualifies on its own. BMI 30 or higher qualifies with heart failure with preserved ejection fraction, uncontrolled hypertension above 140/90 on two or more medications, or chronic kidney disease stage 3a or worse. BMI 27 or higher qualifies with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease. You must be 18 or older. Type 2 diabetes, moderate to severe sleep apnea, and noncirrhotic MASH are excluded, because Part D already covers those routes.

The mechanics matter as much as the criteria. The drug has to be prescribed alongside current and ongoing lifestyle modification with structured nutrition and physical activity, and the prescriber attests to it under penalty of perjury. The pharmacy submits the claim first, which triggers prior authorization back to the prescriber, with a decision inside 72 hours. There is no appeal, only resubmission with corrected information. And the $50 does not count toward the Part D deductible or the $2,100 out-of-pocket cap, because the Bridge sits outside Part D.

Here is the trap I want every patient and every front desk to know about. A patient with a BMI of 32 and nothing on the tier 2 list does not qualify, even though the FDA label would allow treatment at BMI 27 with any weight-related condition. Bring the numbers to the visit: BMI, the last blood pressure and how many medications it took, the last A1c, kidney function, and any heart or vascular history. KFF estimates about 3.8 million beneficiaries met these criteria in 2023, roughly 8 percent of Part D enrollees. Millions more will read the headline and assume they are covered.

The Arizona Obesity Organization has put the whole program online at ArizonaObesity.org: a guide for clinicians covering the tiers, the drug list, the attestation and the prior authorization mechanics, and a companion guide written for patients. If you are the patient, go check those criteria against your own numbers before the visit. Print it for your parents. It answers most of the phone calls before they happen.

The benefit Medicare has covered since 2011 that almost nobody uses

CMS National Coverage Determination 210.12 · Dewar S, Bynum J, Batsis JA. J Gen Intern Med. 2020;35(1):368-370

Intensive Behavioral Therapy for obesity has been covered since November 29, 2011. BMI 30 or higher, up to 22 visits in a year, no copay and no deductible. Weekly in month one, every other week through month six, then monthly for the rest of the year for patients who have lost at least 3 kg by the six-month mark. There are codes for individual visits (G0447) and, since 2015, for group visits (G0473).

Uptake in the benefit's first four years was under one percent of beneficiaries with obesity, between 3.5 and 7.3 per 1,000 from 2012 to 2015. Not because of cost, because it is free. The benefit has to be furnished by a primary care physician or practitioner in a primary care setting. Specialty obesity clinics cannot bill it. Dietitians and nurses can deliver the sessions under supervision, but cannot bill for them directly. We built a benefit and then put it in the one room that has the least time to deliver it.

Dietitian coverage carries its own asterisk. Medical nutrition therapy has been a Part B benefit since 2002, and registered dietitians bill it directly for diabetes, non-dialysis kidney disease, and 36 months after a kidney transplant. Obesity alone does not qualify. Neither does prediabetes. The Medical Nutrition Therapy Act (H.R. 6199 and S. 3934) would add them; it has been introduced and has not passed. Until then, the way a dietitian reaches a patient with obesity is through primary care, or through a Medicare Advantage supplemental benefit.

What is proposed for next year is worth two minutes of your time. The CY 2027 Physician Fee Schedule proposed rule would pay nationally for health and well-being coaching, individual codes 0591T and 0592T and group code 0593T, delivered by trained coaches under a Medicare practitioner. Comments close September 14, 2026, which is Monday. It would also make nutrition therapy and diabetes self-management training stand-alone billable visits in rural health clinics.

My read: coverage was never the barrier on the lifestyle side. Delivery rules were. And the Bridge quietly changed the calculus, because a prescriber now has to attest to ongoing lifestyle treatment. Intensive Behavioral Therapy in primary care is the covered, documented way to make that attestation true. Fifteen years late, the least-used benefit in Medicare's obesity portfolio suddenly has a reason to exist.

The other half of the country still has nothing

KFF, Medicaid Coverage of and Spending on GLP-1s, January 16, 2026 · The RX Index, 50-state tracker, April 10, 2026

Medicaid puts weight-loss agents on an optional exclusion list, so each state decides. Every state must cover GLP-1s for type 2 diabetes. For obesity itself, 13 state programs covered them as of January 2026, down from 16 the previous fall. California, New Hampshire, Pennsylvania, and South Carolina all ended coverage on January 1, citing utilization above budget. North Carolina ended it in October 2025 and reinstated it in December. Michigan narrowed to severe obesity. Massachusetts added restrictions in July.

Run the arithmetic and it is bleak. About 80 percent of adult Medicaid enrollees live in a state with no pathway to obesity medication, and nearly 40 percent of adults on Medicaid have obesity. This is the population with the least access to everything else that works, and it is the population whose coverage is decided fresh every budget cycle. I keep the state-by-state detail on an interactive map in my content library, including what each covering state requires and which four just dropped out, and I update it as states move.

Arizona is one of the states that says no. AHCCCS covers GLP-1s for type 2 diabetes and covers Wegovy with prior authorization for cardiovascular risk reduction, but not for obesity itself. In December an AHCCCS representative put the current spend at about $73 million a year, $13 million of it from the state general fund. The study committee created by SB 1711 finished its work and adopted recommendations in December 2025, including recognizing obesity as a chronic disease. SB 1621, which would have created a permanent advisory council, passed the Senate on March 11 and died in the House.

There is a price on the table for any state that wants it. The BALANCE Model offers states a confidentially negotiated net price plus a manufacturer-funded lifestyle program for enrollees. States can opt in through January 1, 2027, and it runs through 2031. As of the CMS update on August 14, no participating state had been publicly named. One clarification, because I hear these two conflated constantly: BALANCE is not the $50 Medicare program. They are different things, and the Part D half of BALANCE was delayed indefinitely in April.

When Arizona's Family asked me in July what happens to Arizonans on Medicaid now that Medicare has moved, I said what the record says: there is no coverage for obesity, it was not approved in the budget. That has not changed since. Arizona is not waiting on evidence. It is waiting on a vote.